Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 S-IROX neoadjuvant chemotherapy for borderline resectable pancreatic cancer
jRCTs031180263Phase 2Completed
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan + oxaliplatin + S-1 in pancreatic cancer (PC). Primary endpoint: R0 resection rate. Started May 2018; status: completed.
02
Drugs
irinotecan + oxaliplatin + S-1
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs031180263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180263.